par Hoskins, P;Vergote, Ignace;Cervantes, Andrés;Tu, Dongsheng;Stuart, G;Zola, Paolo;Poveda, Andrés;Provencher, D;Katsaros, D;Ojeda, B;Ghatage, P;Grimshaw, Rachel;Casado, M.;Elit, L;Mendiola, César;Sugimoto, A;D'Hondt, Veronique ;Ozaita, Andrés;Germa, J R;Roy, M;Brotto, L;Chen, Dan;Eisenhauer, Elizabeth
Référence Journal of the National Cancer Institute, 102, 20, page (1547-1556)
Publication Publié, 2010-10
Référence Journal of the National Cancer Institute, 102, 20, page (1547-1556)
Publication Publié, 2010-10
Article révisé par les pairs
Titre: |
|
Auteur: | Hoskins, P; Vergote, Ignace; Cervantes, Andrés; Tu, Dongsheng; Stuart, G; Zola, Paolo; Poveda, Andrés; Provencher, D; Katsaros, D; Ojeda, B; Ghatage, P; Grimshaw, Rachel; Casado, M.; Elit, L; Mendiola, César; Sugimoto, A; D'Hondt, Veronique; Ozaita, Andrés; Germa, J R; Roy, M; Brotto, L; Chen, Dan; Eisenhauer, Elizabeth |
Informations sur la publication: | Journal of the National Cancer Institute, 102, 20, page (1547-1556) |
Statut de publication: | Publié, 2010-10 |
Sujet CREF: | Cancérologie |
MeSH keywords: | Adult |
Aged | |
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use | |
Carboplatin -- administration & dosage | |
Carcinoma -- drug therapy -- secondary | |
Cisplatin -- administration & dosage -- adverse effects | |
Disease-Free Survival | |
Drug Administration Schedule | |
Drug Resistance, Neoplasm | |
Female | |
Humans | |
Middle Aged | |
Neoplasm Staging | |
Odds Ratio | |
Ovarian Neoplasms -- drug therapy -- pathology | |
Paclitaxel -- administration & dosage | |
Topotecan -- administration & dosage -- adverse effects | |
Treatment Failure | |
Note générale: | Clinical Trial, Phase III |
Comparative Study | |
Journal Article | |
Randomized Controlled Trial | |
Research Support, Non-U.S. Gov't | |
SCOPUS: ar.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:0027-8874 |
info:doi/10.1093/jnci/djq362 | |
info:pii/djq362 | |
info:scp/77958520845 | |
info:pmid/20937992 |